Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-05-31

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment.

The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

NCT00051012

Lymphoma, T-Cell, Cutaneous Mycosis Fungoides Sezary Syndrome

COMPLETED PHASE4

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999

Lymphoma, T-Cell, Cutaneous Mycosis Fungoides Sezary Syndrome

COMPLETED PHASE4

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

NCT00051025

Non-Hodgkin's Lymphoma Lymphoma, B-cell Lymphoma, Low-grade

COMPLETED PHASE2

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

NCT03292406

Cutaneous T Cell Lymphoma

COMPLETED PHASE2

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

NCT00460109

Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, T-Cell, Cutaneous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ONTAK (denileukin difitox, DAB389IL-2)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persistent or recurrent cutaneous T-cell lymphoma (CTCL) Stage IB-IVA as defined by TNM staging.
* Pathologic proven diagnosis (cytologically confirmed) of CTCL documented in patient history.
* Preserved organ function: Creatinine and/or Liver Function levels \<1.5 times institutional upper limits of normal (ULN).
* Adequate liver function as indicated by bilirubin \< or equal to 1.5 times ULN, ALT \< or equal to 2 times ULN, AST \< or equal to 2 times ULN.
* Albumin \>3.0 g/dL
* Adequate renal function as indicated by SCr \< or equal to 2.5 mg/dl.
* ECOG performance status between 0-2.
* Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period.
* Patients over the age of 18 who are willing and able to provide Informed Consent.

Exclusion Criteria

* Pathology consistent with peripheral T-cell lymphoma.
* Stage IVB (visceral involvement with CTCL, other than lymph node involvement).
* History of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection.
* Patients who are pregnant or breast feeding.
* Allergy to or have history of allergy to diphtheria toxin or IL-2.
* Previous ONTAK® usage.
* Unstable cardiovascular disease.
* Patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. Exception: Clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy.
* Ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No